Talisman develops therapeutics for Alzheimer's and other neurodegenerative diseases. We provide access to our iPSC platform to support external R&D partnerships.
Harness Therapeutics is focused on developing disease-modifying therapies for neurodegenerative diseases through innovative RNA translation methodologies.
Alchemab Therapeutics is dedicated to harnessing the power of the immune system to develop innovative antibody therapeutics for hard-to-treat diseases.
DefiniGEN is a specialist contract research organisation (CRO) focused on delivering innovative liver and metabolic disease models through its proprietary iPSC-derived technology.
Company Details
Talisman Therapeutics is operated by Talisman Therapeutics Limited and is a Active company incorporated on 4 April 2013 with the registered office located in Cambridge, Cambridgeshire. Talisman Therapeutics Limited was registered 12 years ago.